Skip to main content English

Publikationen 2017

  • Beinhardt S, Al-Zoairy R, Kozbial K, Stättermayer AF, Maieron A, Stauber R, Strasser M, Zoller H, Graziadei I, Rasoul-Rockenschaub S, Trauner M, Ferenci P, Hofer H.
    Long-term follow-up of ribavirin-free DAA-based treatment in HCV-recurrence after orthotopic liver transplantation.
    Liver Int. 2017 Dec 2.
  • F. Bruschi F, T. Claudel, M. Tardelli, A. Caligiuri, TM. Stulnig, F. Marra, M. Trauner
    The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells.
    Hepatology. 2017 Jun;65(6):1875-1890
  • T. Bucsics, M. Schoder, N. Goeschl, P. Schwabl, M. Mandorfer, M. Diermayr, M. Feldner, F. Riedl, D. Bauer, B. Angermayr, M. Cejna, A. Ferlitsch, W. Sieghart, M. Trauner, M. Peck-Radosavljevic, J. Karner, F. Karnel, T. Reiberger
    Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice.
    Dig Liver Dis. 2017, 49(12):1360-1367
  • T. Bucsics, E. Krones
    Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome.
    Gastroenterol Rep (Oxf). 2017 May;5(2):127-137
  • Bucsics T, Hoffman S, Grünberger J, Schoder M, Matzek W, Stadlmann A, Mandorfer M, Schwabl P, Ferlitsch A, Peck-Radosavljevic M, Trauner M, Karner J, Karnel F, Reiberger T.
    ePTFE-TIPS versus repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.
    Liver Int. 2017 Nov 1.
  • D. Chromy, P. Schwabl, T. Bucsics, B. Scheiner, R. Strassl, F. Mayer, MC. Aichelburg, K. Grabmeier-Pfistershammer, M. Trauner, M. Peck-Radosavljevic, T. Reiberger, M. Mandorfer
    Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients.
    Wien Klin Wochenschr. 2017 Jul 25
  • RA. Seidel, T. Claudel*, FA. Schleser, NK. Ojha, M. Westerhausen, S. Nietzsche, C. Sponholz, F. Cuperus, SM. Coldewey, SH. Heinemann, G. Pohnert, M. Trauner, M. Bauer
    Impact of higher-order heme degradation products on hepatic function and hemodynamics.
    J Hepatol. 2017 Aug;67(2):272-281
  • W. Dolak, H. Schwaighofer, B. Hellmich, B. Stadler, G. Spaun, W. Plieschnegger, A. Hebenstreit, J. Weber-Eibel, F. Siebert, K. Emmanuel, P. Knoflach, M. Gschwantler, W. Vogel, M. Trauner, A. Püspök; Austrian PDT study group.
    Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications.
    United European Gastroenterol J. 2017 Feb;5(1):104-110
  • W. Eigner, K. Bashir, C. Primas, L. Kazemi-Shirazi, F. Wrba, M. Trauner, H. Vogelsang
    Dynamics of occurrence of refractory coeliac disease and associated complications over 25 years.
    Aliment Pharmacol Ther. 2017 Jan;45(2):364-372
  • P. Ferenci
    Hepatic encephalopathy.
    Gastroenterol Rep (Oxf). 2017 May;5(2):138-147
  • P. Ferenci
    Diagnosis of Wilson disease.
    Handb Clin Neurol. 2017;142:171-180
  • Gschwantler M, Laferl H, Vogel W, Korak W, Moser S, Hofer H, Bauer B, Schleicher M, Bognar B, Bischof M, Stauber R, Maieron A, Ferenci P; Austrian Hepatitis Study Group.
    Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.
    Wien Klin Wochenschr. 2017 Sep 12
  • P. Ferenci
    New anti-HCV drug combinations: who will benefit?
    Lancet Infect Dis. 2017 17(10):1008-1009
  • M. Ferlitsch, A. Moss, C. Hassan, P. Bhandari, JM. Dumonceau, G. Paspatis, R. Jover, C. Langner, M. Bronzwaer, K. Nalankilli, P. Fockens, R. Hazzan, IM. Gralnek, M. Gschwantler, E. Waldmann, P. Jeschek, D. Penz, D. Heresbach, L. Moons, A. Lemmers, K. Paraskeva, J. Pohl, T. Ponchon, J. Regula, A. Repici, MD. Rutter, NG. Burgess, MJ. Bourke
    Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline.
    Endoscopy. 2017 Mar;49(3):270-297
  • Ferlitsch M.
    To play or not to play - with the adenoma detection rate.
    Endoscopy. 2017 Nov;49(11):1029-1030
  • Gessl I, Waldmann E, Britto-Arias M, Penz D, Pablik E, Trauner M, Ferlitsch M.
    Surveillance colonoscopy in Austria: Are we following the guidelines?
    Endoscopy. 2017 Oct 24.
  • Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B, Reiberger T, Ferlitsch M, Gerner C, Trauner M, Peck-Radosavljevic M, Ferlitsch A.
    Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension.
    Aliment Pharmacol Ther. 2017 Nov 3.
  • CD. Fuchs, P. Schwabl, T. Reiberger, M. Trauner
    Liver Capsule: FXR agonists against liver disease.
    Hepatology. 2016 Nov;64(5):1773
  • CD. Fuchs, G. Paumgartner, A. Wahlström, P. Schwabl, T. Reiberger, N. Leditznig, T. Stojakovic, N. Rohr-Udilova, P. Chiba, HU. Marschall, M. Trauner
    Metabolic preconditioning protects BSEP/ABCB11-/- mice against cholestatic liver injury.
    J Hepatol. 2017 Jan;66(1):95-101
  • C. Fuchs, T. Claudel, H. Scharnagl, T. Stojakovic, M. Trauner
    FXR controls CHOP expression in steatohepatitis.
    FEBS Lett. 2017 17(10):1008-1009
  • K.Staufer, K. Roedl, D. Kivaranovic, A. Drolz, T. Horvatits, S. Rasoul-Rockenschaub, C. Zauner, M. Trauner, V. Fuhrmann
    Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications.
    Liver Int. 2017 Jun;37(6):843-850
  • Granofszky N, Lang M, Khare V, Schmid G, Scharl T, Ferk F, Jimenez K, Knasmüller S, Campregher C, Gasche C.
    Identification of PMN-released Mutagenic Factors in a Co-culture Model for Colitis-associated Cancer.
    Carcinogenesis. 2017 Nov
  • Hou, J.K., Gasche, C., Drazin, N.Z., Weaver, S.A., Ehrlich, O.G., Oberai, R., Zapala, S., Siegel, C.A. and Melmed, G.
    Assessment of Gaps in Care and the Development of a Care Pathway for Anemia in Patients with Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2017 Jan;23(1):35-43
  • E. Halilbasic, D. Steinacher, M. Trauner
    norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
    Dig Dis. 2017;35(3):288-292.
  • J. Hammer, M. Führer
    Lack of an Effect of Gastric Capsaicin on the Rectal Component of the Gastrocolonic Response.
    Dig Dis Sci. 2017 62(12):3542-3549
  • T. Horvatits, A. Drolz, K. Roedl, K. Rutter, A. Ferlitsch, G. Fauler, M. Trauner, V. Fuhrmann
    Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis.
    Liver Int. 2017 Feb;37(2):224-231
  • T. Horvatits, A. Drolz, K. Rutter, K. Roedl, L. Langouche, G. Van den Berghe, G Fauler, B. Meyer, M. Hülsmann, G. Heinz, M. Trauner, V. Fuhrmann
    Circulating bile acids predict outcome in critically ill patients.
    Ann Intensive Care. 2017 Dec;7(1):48
  • Kozbial K, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R, Laferl H, Strasser M, Beinhardt S, Stättermayer AF, Gschwantler M, Zoller H, Maieron A, Graziadei I, Trauner M, Steindl-Munda P, Hofer H, Ferenci P.
    Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
    Liver Int. 2017 Nov 14.
  • M. Lang, D. Berry, K. Passecker, I. Mesteri, S. Bhuju, F. Ebner, V. Sedlyarov, R. Evstatiev, K. Dammann, A. Loy, O. Kuzyk, P. Kovarik, V. Khare, M. Beibel, G. Roma, N. Meisner-Kober, C. Gasche
    HuR Small-Molecule Inhibitor Elicits Differential Effects in Adenomatosis Polyposis and Colorectal Carcinogenesis.
    Cancer Res. 2017 May 1;77(9):2424-2438
  • M. Mandorfer, T. Reiberger
    Beta blockers and cirrhosis, 2016.
    Dig Liver Dis. 2017 Jan;49(1):3-10
  • M. Mandorfer, M. Peck-Radosavljevic, T. Reiberger
    Prevention of progression from small to large varices: are we there yet? An updated meta-analysis.
    Gut. 2017 Jul;66(7):1347-1349
  • G. Moser, J. Peter
    [Brain-gut axis and gut-directed hypnosis - success of an integrated psychosomatic treatment in gastroenterology].
    Z Psychosom Med Psychother. 2017 Mar;63(1):5-19
  • G. Moser, C. Fournier, J. Peter
    Intestinal microbiome-gut-brain axis and irritable bowel syndrome.
    Wien Med Wochenschr. 2017 Sep 8
  • Mueller M, Castro RE, Thorell A, Marschall HU, Auer N, Herac M, Rodrigues CMP, Trauner M.
    Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients.
    Liver Int. 2017 Aug 29.
  • R. Paternostro, D. Wagner, T. Reiberger, M. Mandorfer, R. Schwarzer, M. Ferlitsch, M. Trauner, M. Peck-Radosavljevic, A. Ferlitsch
    Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis.
    Wien Klin Wochenschr. 2017 Jan;129(1-2):8-15
  • R. Paternostro, T. Reiberger, M. Mandorfer, R. Schwarzer, P. Schwabl, S. Bota, M. Ferlitsch, M. Trauner, M. Peck-Radosavljevic, A. Ferlitsch
    Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis.
    J Gastroenterol Hepatol. 2017 Jan;32(1):184-190
  • M. Pinter, L. Haupt, F. Hucke, S. Bota, T. Bucsics, M. Trauner, M. Peck-Radosavljevic, W. Sieghart
    The impact of thyroid hormones on patients with hepatocellular carcinoma.
    PLoS One. 2017 Aug 3;12(8):e0181878
  • Pinter M, Jain RK.
    Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.
    Sci Transl Med. 2017 Oct 4;9(410)
  • Pinter M, Weinmann A, Wörns MA, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W.
    Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.
    United European Gastroenterol J. 2017 Nov;5(7):987-996
  • S. Steiner, T. Bucsics, P. Schwabl, M. Mandorfer, B. Scheiner, MC. Aichelburg, K. Grabmeier-Pfistershammer, P. Ferenci, M. Trauner, M. Peck-Radosavljevic, T. Reiberger
    Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.
    Wien Klin Wochenschr. 2017
  • T. Reiberger, M. Mandorfer
    Beta adrenergic blockade and decompensated cirrhosis.
    J Hepatol. 2017 Apr;66(4):849-859
  • T. Reiberger, J. Trebicka
    New liver - Fresh microbiome: Implications on brain function.
    Liver Transpl. 2017 Jul;23(7):873-874
  • Lo GH, Reiberger T.
    Peptic ulcer bleeding in cirrhotic patients: Is as bad as variceal bleeding?
    Hepatology. 2017 Nov 23.
  • Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P.
    Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
    Wien Klin Wochenschr. 2017 Nov;129(Suppl 3):135-158
  • LW. Unger, G. Berlakovich, M. Trauner, T. Reiberger
    Management of portal hypertension before and after liver transplantation.
    Liver Transpl. 2017 Jul 28.
  • S. Vermeire, WJ. Sandborn, S. Danese, X. Hébuterne, BA. Salzberg, M. Klopocka, D. Tarabar, T. Vanasek, M. Greguš, PA. Hellstern, JS. Kim, MP. Sparrow, KJ. Gorelick, M. Hinz, A. Ahmad, V. Pradhan, M. Hassan-Zahraee, R. Clare, F. Cataldi, W. Reinisch
    Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Jul 8;390(10090):135-144
  • W. Reinisch, J. Jahnsen, S. Schreiber, S. Danese, J. Panés, A. Balsa, W. Park, J. Kim, JU. Lee, DH. Yoo
    Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.
    BioDrugs. 2017 Jun;31(3):223-237
  • W. Reinisch, JF. Colombel, G. D'Haens, WJ. Sandborn, P. Rutgeerts, K. Geboes, J. Petersson, S. Eichner, Q. Zhou, AM. Robinson, HA. Read, R. Thakkar
    Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
    J Crohns Colitis. 2017 Apr 1;11(4):425-434
  • JD. Lewis, L. Albenberg, D. Lee, M. Kratz, K. Gottlieb, W. Reinisch
    The Importance and Challenges of Dietary Intervention Trials for Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2017 Feb;23(2):181-191
  • N. Rohr-Udilova, F. Klinglmüller, M. Seif, H. Hayden, M. Bilban, M. Pinter, K. Stolze, W. Sieghart, M. Peck-Radosavljevic, M. Trauner
    Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib.
    Oncotarget. 2017 8(34):57109-57120
  • B. Scheiner, D. Parada-Rodriguez, T. Bucsics, P. Schwabl, M. Mandorfer, N. Pfisterer, F. Riedl, W. Sieghart, A. Ferlitsch, M. Trauner, M. Peck-Radosavljevic, T. Reiberger
    Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.
    Scand J Gastroenterol. 2017 Sep;52(9):1008-1015
  • B. Scheiner, G. Lindner, T. Reiberger, B. Schneeweiss, M. Trauner, C. Zauner, GC. Funk
    Acid-base disorders in liver disease.
    J Hepatol. 2017 Jul 3. pii: S0168-8278(17)32131-1
  • P. Schwabl, M. Mandorfer, S. Steiner, B. Scheiner, D. Chromy, M. Herac, T. Bucsics, H. Hayden, K. Grabmeier-Pfistershammer, A. Ferlitsch, G. Oberhuber, M. Trauner, M. Peck-Radosavljevic, T. Reiberger
    Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease.
    Aliment Pharmacol Ther. 2017 Jan;45(1):139-149
  • P. Schwabl, W. Laleman
    Novel treatment options for portal hypertension.
    Gastroenterol Rep (Oxf). 2017 May;5(2):90-103
  • P. Schwabl, E. Hambruch , BA. Seeland, H. Hayden, M. Wagner, L. Garnys, B. Strobel, TL. Schubert, F. Riedl, D. Mitteregger, M. Burnet, P. Starlinger, G. Oberhuber, U. Deuschle, N. Rohr-Udilova, BK. Podesser, M. Peck-Radosavljevic, T. Reiberger, C. Kremoser, M. Trauner
    The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
    J Hepatol. 2017 Apr;66(4):724-733
  • AF. Stättermayer, S. Traussnigg, E. Aigner, C. Kienbacher, U. Huber-Schönauer, P. Steindl-Munda, A. Stadlmayr, F. Wrba, M. Trauner, C. Datz, P. Ferenci
    Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
    J Trace Elem Med Biol. 2017 Jan;39:100-107
  • K. Staufer, K. Roedl, D. Kivaranovic, A. Drolz, T. Horvatits, S. Rasoul-Rockenschaub, C. Zauner, M. Trauner, V. Fuhrmann
    Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications.
    Liver Int. 2017 Jun;37(6):843-850
  • Staufer K, Dengler M, Huber H, Marculescu R, Stauber R, Lackner C, Dienes HP, Kivaranovic D, Schachner C, Zeitlinger M, Wulkersdorfer B, Rauch P, Prager G, Trauner M, Mikulits W.
    The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis.
    Cell Death Dis. 2017 Oct 26;8(10):e3135
  • M. Tardelli, T. Claudel, F. Bruschi, V. Moreno-Viedma, M. Trauner
    Adiponectin regulates AQP3 via PPARα in human hepatic stellate cells.
    Biochem Biophys Res Commun. 2017 Aug 12;490(1):51-54
  • Tardelli M, Bruschi FV, Claudel T, Moreno-Viedma V, Halilbasic E, Marra F, Herac M, Stulnig TM, Trauner M.
    AQP3 is regulated by PPARγ and JNK in hepatic stellate cells carrying PNPLA3 I148M.
    Sci Rep. 2017 Nov 7;7(1):14661
  • P. Fickert, GM. Hirschfield, G. Denk, HU. Marschall, I. Altorjay, M. Färkkilä, C. Schramm, U. Spengler, R. Chapman, A. Bergquist, E. Schrumpf, F. Nevens, P. Trivedi, FP. Reiter, I. Tornai, E. Halilbasic, R. Greinwald, M. Pröls, MP. Manns, M. Trauner; European PSC norUDCA Study Group
    norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
    J Hepatol. 2017 May 18. pii: S0168-8278(17)32045-7
  • R. Eferl, M. Trauner
    Chromosomal instability in HCC: a key function for checkpoint kinase 2.
    Gut. 2017 May 5. pii: gutjnl-2017-314101
  • Trauner M, Fuchs CD, Halilbasic E, Paumgartner G.
    New therapeutic concepts in bile acid transport and signaling for management of cholestasis.
    Hepatology. 2017 Apr;65(4):1393-1404
  • C. Lackner, R. Bataller, A. Burt, R. Miquel, D. Schuppan, D. Tiniakos, M. Trauner
    Fibrosis evaluation by transient elastography in alcoholic liver disease: Is the histological scoring system impacting cutoff values?
    Hepatology. 2017 May;65(5):1758-1761
  • S. Traussnigg, C. Kienbacher, M. Gajdošík, L. Valkovič, E. Halilbasic, J. Stift, C. Rechling, H. Hofer, P. Steindl-Munda, P. Ferenci, F. Wrba, S. Trattnig, M. Krššák, M. Trauner
    Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
    Liver Int. 2017 37(10):1544-1553
  • Scarpignato C and Dolak W (joint first authours), Lanas A, Matzneller P, Renzulli C, Grimaldi M, Zeitlinger M, Bjarnason I.
    Rifaximin Reduces Number and Severity of Intestinal Lesions Associated With use of Non-steroidal Anti-inflammatory Drugs in Humans.
    Gastroenterology. 2016 Dec 19. pii: S0016-5085(16)35504-4
  • Kunschitz E, Friedrich O, Schöppl C, Weiss TW, Miehsler W, Sipötz J, Moser G
    Assessment of the need for psychosomatic care in patients with suspected cardiac disease.
    Wien Klin Wochenschr. 2017 Apr;129(7-8):225-232
  • Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M.
    Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.
    Hepatology. 2017 Jan;65(1):350-362
  • Roedl K, Wallmüller C, Drolz A, Horvatits T1, Rutter K, Spiel A, Ortbauer J, Stratil P, Hubner P, Weiser C, Motaabbed JK, Jarczak D, Herkner H, Sterz F3, Fuhrmann V.
    Outcome of in- and out-of-hospital cardiac arrest survivors with liver cirrhosis.
    Ann Intensive Care. 2017 Oct 6;7(1):103.